논문KCI 등재
Reply to correspondence 1 on “MET promotes he patocellular carcinoma development through the promotion of TRIB3-mediated FOXO1 degradation”
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
관련 논문AI추천
Reply to correspondence 2 on “MET promotes hepato cellular carcinoma development through the promo tion of TRIB3-mediated FOXO1 degradation”Jae Youn Cheong, Ji Eun Han, Jung Woo Eun, Soon Sun Kim대한간학회 · Clinical and Molecular Hepatology2026 · 제32권 제1호Correspondence to Editorial 2 on “MET promotes hepatocellular carcinoma development through the promotion of TRIB3-mediated FOXO1 degradation”Limin Xia, Tiantian Wang, Wenjie Huang대한간학회 · Clinical and Molecular Hepatology2026 · 제32권 제1호Correspondence to Editorial 1 on “MET promotes he patocellular carcinoma development through the pro motion of TRIB3-mediated FOXO1 degradation”Limin Xia, Tiantian Wang, Wenjie Huang대한간학회 · Clinical and Molecular Hepatology2026 · 제32권 제1호Unveiling TRIB3: A new mediator in MET-driven hepa tocellular carcinoma progression: Editorial on “MET promotes hepatocellular carcinoma development through the promotion of TRIB3-mediated FOXO1 deg radation”Many Sze Man Chan, Terence Kin Wah Lee대한간학회 · Clinical and Molecular Hepatology2026 · 제32권 제1호Uncovering the MET-TRIB3-FOXO1 axis: A novel target in MET-driven hepatocellular carcinoma: Editorial on “MET promotes hepatocellular carcinoma develop ment through the promotion of TRIB3-mediated FOXO1 degradation”Jae Youn Cheong, Ji Eun Han, Jung Woo Eun, Soon Sun Kim대한간학회 · Clinical and Molecular Hepatology2026 · 제32권 제1호MET promotes hepatocellular carcinoma development through the promotion of TRIB3-mediated FOXO1 degradationChenan Fu, Dean Rao, Feimu Fan, Han Li, Huifang Liang, Jie Jin, Junli Lu, Limin Xia, Tiantian Wang, Wenjie Huang, Yiming Luo, Zhoubin Sun대한간학회 · Clinical and Molecular Hepatology2025 · 제31권 제3호
이 간행물의 다른 논문 (76건)
2025 KASL clinical practice guidelines for management of hepatitis CEun Sun Jang, Eun Ju Cho, Chang Hun Lee, Do Seon Song, Nae-Yun Heo, Jae Yoon Jeong, Jung Gil Park, Jae Seung Lee, Jae Hyun Yoon, Seul Ki Han, Young Kul Jungpp. 1-52Critical considerations in evaluating the therapeutic potential of HK-660S for primary sclerosing cholangi tis: Letter to the editor on “Safety and efficacy of HK 660S in patients with primary sclerosing cholangitis: a randomized double-blind phase 2a trial”Yizi He, Haifeng He, Qi Liang, Yongzhi Xiepp. 1-3Letter to the editor on “Current burden of steatotic liv er disease and fibrosis among adults in the United States, 2017–2023”Sisi Yang, Zhenxuan Mapp. 4-6Letter to the editor on “Direct-acting antiviral therapy for patients with HCV-related hepatocellular carcino ma: a nationwide cohort study”Xiaodi Yang, Zhongqing Qian, Qiong Wang, Fuliang Chen, Xiaojing Wang, Deyan Chenpp. 7-9Letter to the editor on “GULP1 as a novel diagnostic and predictive biomarker in hepatocellular carcinoma”Juan Yang, Xinyi Li, Sheng Zhengpp. 10-12